Tambi Jarmi is a Nephrology physician. OpenAlex indexes 66 publications with 547 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4500 San Pablo Rd S
Jacksonville, FL 32224
Telephone
904-953-2000Provider last certified this registry record 1 Sept 2020.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20255 payments$11,596openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year20231 payment
- Aurinia Pharma U.S., Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
51.5%Proton pump inhibitor38.7%Pantoprazole Sodium100%Part D≥29 patientsCorticosteroid8.2%Prednisone100%Part D≥17 patients+ 1 more class in this area
Anti-infectives
30.2%Short-acting sulfonamides16.7%Sulfamethoxazole-Trimethoprim100%Part D≥19 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor9.5%Valganciclovir Hcl100%Part D≥19 patients+ 1 more class in this area
Cardiovascular
18.4%Calcium channel blocker13.1%Nifedipine Er100%Part D≥15 patientsBeta blocker5.2%Carvedilol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Heart Transplantation for Cardiac Amyloidosis: Mayo Clinic Consensus Statement
Mayo Clinic Proceedings
2025 - Machine Learning-Based Risk Prediction of Allograft Rejection within One-Year Post-Transplant for Kidney Transplant Patients
American Journal of Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”